Navigation Links
Auxogyn Announces Issuance of Key Patent Covering Predictive Embryo Assessment Parameters for In Vitro Fertilization

MENLO PARK, Calif., June 27, 2011 /PRNewswire/ -- Auxogyn, Inc., a privately held medical technology company focused on women's reproductive health, today announced that the U.S. Patent and Trademark Office (USPTO) issued patent number 7,963,906 covering three predictive parameters for the assessment of embryo viability during in vitro fertilization (IVF) procedures used in Auxogyn's early embryo viability assessment (Eeva™) System.

"This patent is the first to issue from a portfolio of patents filed related to our Eeva System in the United States, Europe and other countries," said Lissa Goldenstein, president and chief executive officer of Auxogyn. "We believe the value of our technology lies in the unique ability of our proprietary parameters to evaluate and predict, by day 2, the embryos that will continue development to blastocyst stage, which happens on day 5 of human development. By providing novel clinical data to IVF clinicians early, this non-invasive clinical tool has the potential to improve clinical pregnancy rates for IVF patients."

The Eeva System uses proprietary software to measure the three predictive parameters from time lapse video images of the embryos developing in a standard incubator and identify  on day 2 which embryos are most likely to continue development into blastocysts (day 5). Blastocyst formation is a critical milestone in human embryo development and provides objective criteria for selecting which embryo(s) to transfer. Use of the Eeva System is investigational, and the Eeva System has not been cleared by the U.S. Food and Drug Administration for commercial sale.

Auxogyn's proprietary non-invasive Eeva System is based on research of early human embryo development conducted at Stanford University and published in the October 2010 issue of Nature Biotechnology. The U.S. patent 7,963,906 was issued to Stanford University. Auxogyn has an exclusive license from Stanford University with worldwide rights to develop products based on intellectual property that includes this patent.

About Auxogyn

Auxogyn is a privately held medical technology company focused on advancing women's reproductive health by applying its novel scientific and clinical knowledge of early human developmental biology to the field of assisted reproduction and in vitro fertilization procedures. Auxogyn is funded by the leading life science venture firms Kleiner Perkins Caufield & Byers, TPG Biotechnology and Merck Serono Ventures. For more information regarding Auxogyn please visit

SOURCE Auxogyn, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
(Date:11/30/2015)... Belgium , Nov. 30, 2015   ... focused on developing blood-based diagnostic tests for a broad range ... will present at the LD Micro Conference, which will be ... CA. Attending from VolitionRx will be David ... Powell , Vice President of Investor Relations. ® ...
(Date:11/30/2015)... Israel , Nov. 30, 2015  OticPharma, ... acquiring and developing innovative therapies for ear, nose, and ... Keith A. Katkin as chairman of the company,s ... chief executive officer for OticPharma, Ltd.  "Keith brings a ... he will be able to share this experience and ...
(Date:11/29/2015)... Nov. 29, 2015   Royal Philips  (NYSE: PHG, ... solutions at the 2015 Radiological Society of North America ... McCormick Place in Chicago . Visitors ... the company,s broad portfolio of integrated Diagnostic Imaging, Clinical ... increase clinical performance, improve workflow and create a superior ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... is one of a select few plastic surgeons in the New York City ... , SculpSure™ is the world’s first heat-induced laser treatment for fat loss in ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... ), a leading provider of enterprise Time and Attendance/Workforce Management cloud-based solutions, ... the Microsoft Partner Program with competencies in the Application Development, demonstrating a ...
(Date:11/30/2015)... ... November 30, 2015 , ... Workstation solutions provider ... 30 HealthPostures’ dealers located throughout the United States, is OneStop Ergonomics. The addition ... industrial, manufacturing and government workers and organizational leaders that are introduced to innovative ...
(Date:11/30/2015)... ... November 30, 2015 , ... CTI Group (Holdings) Inc. ... organizations through communication analytics, announced today that their Proteus® VoIP QMS solution now ... quality. , Proteus® VoIP QMS (Quality Management System) does this by ...
(Date:11/29/2015)... (PRWEB) , ... November 30, 2015 , ... The Cyber Monday deal is a deep ... is the right time to get gifts for the skin care lover in your circle. ... filled with serums . This year, the 3 serums are staples: Collagen, Retinol and Hyaluronic ...
Breaking Medicine News(10 mins):